BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 16804036)

  • 21. Recovery of hormone secretion after chronic gonadotropin-releasing hormone agonist administration in women with polycystic ovarian disease.
    de Ziegler D; Steingold K; Cedars M; Lu JK; Meldrum DR; Judd HL; Chang RJ
    J Clin Endocrinol Metab; 1989 Jun; 68(6):1111-7. PubMed ID: 2524501
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.
    Pasquali R; Gambineri A; Biscotti D; Vicennati V; Gagliardi L; Colitta D; Fiorini S; Cognigni GE; Filicori M; Morselli-Labate AM
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2767-74. PubMed ID: 10946879
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhanced granulosa cell responsiveness to follicle-stimulating hormone during insulin infusion in women with polycystic ovary syndrome treated with pioglitazone.
    Coffler MS; Patel K; Dahan MH; Yoo RY; Malcom PJ; Chang RJ
    J Clin Endocrinol Metab; 2003 Dec; 88(12):5624-31. PubMed ID: 14671144
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hormonal and clinical effects of GnRH agonist alone, or in combination with a combined oral contraceptive or flutamide in women with severe hirsutism.
    De Leo V; Fulghesu AM; la Marca A; Morgante G; Pasqui L; Talluri B; Torricelli M; Caruso A
    Gynecol Endocrinol; 2000 Dec; 14(6):411-6. PubMed ID: 11228061
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Endocrine studies of normal and polycystic ovarian tissues in vitro.
    Wilson EA; Erickson GF; Zarutski P; Finn AE; Tulchinsky D; Ryan KJ
    Am J Obstet Gynecol; 1979 May; 134(1):56-63. PubMed ID: 220877
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact of obesity and chronic hyperinsulinemia on gonadotropin release and gonadal steroid secretion in the polycystic ovary syndrome.
    Dunaif A; Mandeli J; Fluhr H; Dobrjansky A
    J Clin Endocrinol Metab; 1988 Jan; 66(1):131-9. PubMed ID: 2961783
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Estrogens, progestogens, and androgens enhance the follicle-stimulating hormone-stimulated plasminogen activator production by cultured rat granulosa cells.
    Wang C; Leung A
    Endocrinology; 1987 May; 120(5):2131-6. PubMed ID: 3106015
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Serum levels of anti-muller hormone in women with polycystic ovary syndrome and healthy women of reproductive age].
    Parahuleva N; Pehlivanov B; Orbecova M; Deneva T; Uchikova E
    Akush Ginekol (Sofiia); 2013; 52 Suppl 1():16-23. PubMed ID: 24294740
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Elevated serum levels of free insulin-like growth factor I in polycystic ovary syndrome.
    Thierry van Dessel HJ; Lee PD; Faessen G; Fauser BC; Giudice LC
    J Clin Endocrinol Metab; 1999 Sep; 84(9):3030-5. PubMed ID: 10487660
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Suppression and recovery of gonadotropin and steroid secretion by a gonadotropin-releasing hormone receptor antagonist in healthy women with normal ovulation versus women with polycystic ovary syndrome in the early follicular phase.
    Sagnella F; Apa R; Guido M; Villa P; Spadoni V; Miceli F; Lanzone A
    Fertil Steril; 2009 May; 91(5):1857-63. PubMed ID: 18538325
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inappropriate gonadotropin secretion in polycystic ovary syndrome: influence of adiposity.
    Arroyo A; Laughlin GA; Morales AJ; Yen SS
    J Clin Endocrinol Metab; 1997 Nov; 82(11):3728-33. PubMed ID: 9360532
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Androgen response in polycystic ovarian syndrome to FSH treatment after LHRH agonist suppression.
    Hamori M; Zwirner M; Clédon P; Tinneberg HR
    Int J Fertil; 1992; 37(3):171-5. PubMed ID: 1355764
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adrenal abnormalities in polycystic ovary syndrome.
    Loughlin T; Cunningham S; Moore A; Culliton M; Smyth PP; McKenna TJ
    J Clin Endocrinol Metab; 1986 Jan; 62(1):142-7. PubMed ID: 3079598
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The effects of FSH,LH and insulin on steroids production by granulosa cells from polycystic ovaries syndrome].
    Wang A; Lu C; Qiao J
    Zhonghua Yi Xue Za Zhi; 1998 Nov; 78(11):830-2. PubMed ID: 11038778
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recombinant human follicle-stimulating hormone stimulates multiple follicular growth, but minimal estrogen production in gonadotropin-releasing hormone antagonist-treated monkeys: examining the role of luteinizing hormone in follicular development and steroidogenesis.
    Karnitis VJ; Townson DH; Friedman CI; Danforth DR
    J Clin Endocrinol Metab; 1994 Jul; 79(1):91-7. PubMed ID: 8027261
    [TBL] [Abstract][Full Text] [Related]  

  • 36. GH release after GHRH plus arginine administration in obese and overweight women with polycystic ovary syndrome.
    Orio F; Palomba S; Colao A; Russo T; Dentico C; Tauchmanovà L; Savastano S; Nappi C; Sultan C; Zullo F; Lombardi G
    J Endocrinol Invest; 2003 Feb; 26(2):117-22. PubMed ID: 12739737
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impaired insulin action on granulosa-lutein cells in women with polycystic ovary syndrome and insulin resistance.
    Fedorcsák P; Storeng R; Dale PO; Tanbo T; Abyholm T
    Gynecol Endocrinol; 2000 Oct; 14(5):327-36. PubMed ID: 11109972
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of flutamide on pituitary and adrenal responsiveness to corticotrophin releasing factor (CRF).
    De Leo V; la Marca A; Lanzetta D; Cariello PL; D'Antona D; Morgante G
    Clin Endocrinol (Oxf); 1998 Jul; 49(1):85-9. PubMed ID: 9797851
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Obese patients with polycystic ovary syndrome: evidence that metformin does not restore sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by ovarian steroids.
    Eagleson CA; Bellows AB; Hu K; Gingrich MB; Marshall JC
    J Clin Endocrinol Metab; 2003 Nov; 88(11):5158-62. PubMed ID: 14602743
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Disruption of the synchronous secretion of leptin, LH, and ovarian androgens in nonobese adolescents with the polycystic ovarian syndrome.
    Veldhuis JD; Pincus SM; Garcia-Rudaz MC; Ropelato MG; Escobar ME; Barontini M
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3772-8. PubMed ID: 11502810
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.